Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA2118 in postmenopausal women with low bone mineral density
NCT06577935Phase 2Active, not recruiting
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of AGA2118 in postmenopausal osteoporosis, sponsored by Angitia Biopharmaceuticals. Started Oct 2024; status: active, not recruiting.
02
Drugs
AGA2118
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT06577935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577935.